Stemline Therapeutics Inc (NASDAQ:STML)

Delayed Data
As of Apr 24
 -0.42 / -2.47%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering, acquiring, developing and commercializing oncology therapeutics that target both cancer stem cells and tumor bulk. It currently developing two clinical stage products: SL-401 and SL-701. The lead indication for SL-401, a biologic targeted therapy is acute myeloid leukemia. The lead indications for SL-701, a therapeutic cancer vaccine comprised of synthetic peptides that correspond to specific targets, called epitopes, on cancer stem cells and tumor bulk of brain cancer, are pediatric and adult brain cancer. It also develops a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Contact Information

Stemline Therapeutics, Inc.
750 Lexington Avenue
New York New York 10022
P:(646) 502-2310
Investor Relations:



Mutual fund holders32.93%
Individual stakeholders13.17%
Other institutional10.32%

Top Executives

Ivan BergsteinChairman, President & Chief Executive Officer
Kenneth HobermanChief Operating Officer & Secretary
David G. GioncoChief Accounting Officer & Vice President-Finance
Eric K. RowinskyChief Medical Officer, Head-Research & Development
Michael SzarekHead-Clinical & Regulatory Affairs

To view my watchlist

Not a member yet?

Sign up now for a free account